FDA Issues Complete Response Letter to Sotorasib for KRAS G12C–Mutated NSCLC

1 year ago 51

The FDA has issued a complete response letter to the supplemental new drug application seeking the full approval of sotorasib for patients with KRAS G12C–mutated non–small cell lung cancer.

1. Homepage
2. Lung Cancer
3. FDA Issues Complete Response Letter to Sotorasib for KRAS G12C–Mutated NSCLC